Base de dados : MEDLINE
Pesquisa : D12.644.861.847 [Categoria DeCS]
Referências encontradas : 57 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 6 ir para página                

  1 / 57 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28557747
[Au] Autor:Williams FLR; Ogston S; Hume R; Watson J; Stanbury K; Willatts P; Boelen A; Juszczak E; Brocklehurst P; I2S2 Team
[Ad] Endereço:Division of Population Health Sciences, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom; f.l.r.williams@dundee.ac.uk.
[Ti] Título:Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years: An RCT.
[So] Source:Pediatrics;139(5), 2017 May.
[Is] ISSN:1098-4275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The recommendation for enteral iodide intake for preterm infants is 30 to 40 µg/kg per day and 1 µg/kg per day for parenteral intake. Preterm infants are vulnerable to iodide insufficiency and thyroid dysfunction. The hypothesis tested whether, compared with placebo, iodide supplementation of preterm infants improves neurodevelopment. METHODS: A randomized controlled trial of iodide supplementation versus placebo in infants <31 weeks' gestation. Trial solutions (sodium iodide or sodium chloride; dose 30 µg/kg per day) were given within 42 hours of birth to the equivalent of 34 weeks' gestation. The only exclusion criterion was maternal iodide exposure during pregnancy or delivery. Whole blood levels of thyroxine, thyrotropin, and thyroid-binding globulin were measured on 4 specific postnatal days. The primary outcome was neurodevelopmental status at 2 years of age, measured by using the Bayley Scales of Infant Development-III. The primary analyses are by intention-to-treat, and data are presented also for survivors. RESULTS: One thousand two hundred seventy-three infants (637 intervention, 636 placebo) were recruited from 21 UK neonatal units. One hundred thirty-one infants died, and neurodevelopmental assessments were undertaken in 498 iodide and 499 placebo-supplemented infants. There were no significant differences between the intervention and placebo groups in the primary outcome: mean difference cognitive score, -0.34, 95% confidence interval (CI) -2.57 to 1.89; motor composite score, 0.21, 95% CI -2.23 to 2.65; and language composite score, -0.05, 95% CI -2.48 to 2.39. There was evidence of weak interaction between iodide supplementation and hypothyroxinemic status in the language composite score and 1 subtest score. CONCLUSIONS: Overall iodide supplementation provided no benefit to neurodevelopment measured at 2 years of age.
[Mh] Termos MeSH primário: Encéfalo/crescimento & desenvolvimento
Desenvolvimento Infantil/efeitos dos fármacos
Recém-Nascido Prematuro/fisiologia
Iodetos/administração & dosagem
Nutrição Parenteral
[Mh] Termos MeSH secundário: Pré-Escolar
Seguimentos
Seres Humanos
Lactente
Iodetos/efeitos adversos
Nutrição Parenteral/efeitos adversos
Tireotropina/sangue
Tiroxina/sangue
Globulina de Ligação a Tiroxina/metabolismo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRAGMATIC CLINICAL TRIAL
[Nm] Nome de substância:
0 (Iodides); 0 (Thyroxine-Binding Globulin); 9002-71-5 (Thyrotropin); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170810
[Lr] Data última revisão:
170810
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170531
[St] Status:MEDLINE


  2 / 57 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27549767
[Au] Autor:Benvenga S; Guarneri F
[Ad] Endereço:Department of Clinical and Experimental Medicine - Endocrinology, University of Messina, Via Consolare Valeria, 98125, Messina, Italy.
[Ti] Título:Conservation in the phylum of the local homology of apolipoproteins with the thyroid hormone plasma carriers.
[So] Source:Rev Endocr Metab Disord;17(4):537-544, 2016 Dec.
[Is] ISSN:1573-2606
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Thyroxine-binding globulin (TBG), transthyretin (TTR), albumin (HSA), plus other plasmatic proteins, which include apolipoproteins, can bind and transport thyroid hormones (TH). In 1994, a 5-residue motif (Y, L/I/M, X, X, V/L/I) conserved in human TBG, TTR, HSA, and human and animal apolipoproteins was identified. Recently, we noticed that a number of residues upstream and downstream that motif are also conserved.We tested in silico the conservation of this larger motif in the many additional animal sequences of TH plasma carriers discovered after 1994. To this aim, we searched for the occurrence of the "new" motif in human and animal apolipoprotein and non-apolipoprotein TH-binding plasmatic proteins, and in a group of randomly selected proteins (2918 sequences from 56 species) not known as TH binders.Our results confirm the conservation of the "new" motif, associated with TH binding, in a total of 426 sequences analyzed (220 belonging to 169 apolipoproteins from 69 species, 206 belonging to 123 nonapolipoproteins from 54 species). Additionally, we found that within such conserved segments some differences between groups of TH plasma carriers exist. Interestingly, number and type of differences appear related to the affinity of each carrier for thyroid hormones. No occurrence of the motif was found in control proteins (alpha- and beta-tubulin, eosinophil cationic protein, endothelin-1, -2 and -3, IgG receptor, tropomyosin, Wnt inhibitory factor 1, erythropoietin, insulin and haptoglobin).Maintenance of a TH-binding domain in apolipoproteins throughout the phylum should be not less important that maintenance of the lipid binding domain.
[Mh] Termos MeSH primário: Apolipoproteínas/metabolismo
Lipoproteínas/metabolismo
Hormônios Tireóideos/metabolismo
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Pré-Albumina/metabolismo
Globulina de Ligação a Tiroxina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Apolipoproteins); 0 (Lipoproteins); 0 (Prealbumin); 0 (Thyroid Hormones); 0 (Thyroxine-Binding Globulin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160824
[St] Status:MEDLINE
[do] DOI:10.1007/s11154-016-9379-7


  3 / 57 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Maciel, Lea Maria Zanini
[PMID]:27533612
[Au] Autor:Maciel LM
[Ad] Endereço:Divisão de Endocrinologia e Metabologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.
[Ti] Título:Are TSH normal reference ranges adequate for pregnant women?
[So] Source:Arch Endocrinol Metab;60(4):303-6, 2016 Aug.
[Is] ISSN:2359-4292
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Mh] Termos MeSH primário: Gravidez/sangue
Glândula Tireoide/metabolismo
Tireotropina/sangue
[Mh] Termos MeSH secundário: Gonadotropina Coriônica/sangue
Feminino
Idade Gestacional
Seres Humanos
Iodo/deficiência
Trimestres da Gravidez/sangue
Valores de Referência
Testes de Função Tireóidea
Globulina de Ligação a Tiroxina/análise
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (Chorionic Gonadotropin); 0 (Thyroxine-Binding Globulin); 9002-71-5 (Thyrotropin); 9679TC07X4 (Iodine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160818
[St] Status:MEDLINE


  4 / 57 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27528273
[Au] Autor:Ren XM; Qin WP; Cao LY; Zhang J; Yang Y; Wan B; Guo LH
[Ad] Endereço:State Key Laboratory of Environmental Chemistry and Eco-toxicology, Research Center for Eco-environmental Sciences, Chinese Academy of Sciences, 18 Shuangqing Road, Beijing 100085, China.
[Ti] Título:Binding interactions of perfluoroalkyl substances with thyroid hormone transport proteins and potential toxicological implications.
[So] Source:Toxicology;366-367:32-42, 2016 Jul 29.
[Is] ISSN:1879-3185
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Perfluoroalkyl substances (PFASs) have been shown to cause abnormal levels of thyroid hormones (THs) in experimental animals, but the molecular mechanism is poorly understood. Here, a fluorescence displacement assay was used to determine the binding affinities of 16 PFASs with two major TH transport proteins, transthyretin (TTR) and thyroxine-binding globulin (TBG). Most of the tested PFASs bound TTR with relative potency (RP) values of 3×10(-4) to 0.24 when compared with that of the natural ligand thyroxine, whereas fluorotelomer alcohols did not bind. Only perfluorotridecanoic acid and perfluorotetradecanoic acid bound TBG, with RP values of 2×10(-4) when compared with that of thyroxine. Based on these results, it was estimated that displacement of T4 from TTR by perfluorooctane sulfonate and perfluorooctanoic acids would be significant for the occupationally exposed workers but not the general population. Structure-binding analysis revealed that PFASs with a medium chain length and a sulfonate acid group are optimal for TTR binding, and PFASs with lengths longer than 12 carbons are optimal for TBG binding. Three mutant proteins were prepared to examine crucial residues involved in the binding of PFASs to TH transport proteins. TTR with a K15G mutation and TBG with either a R378G or R381G mutation showed decreased binding affinity to PFASs, indicating that these residues play key roles in the interaction with the compounds. Molecular docking showed that the PFASs bind to TTR with their acid group forming a hydrogen bond with K15 and the hydrophobic chain towards the interior. PFASs were modeled to bind TBG with their acid group forming a hydrogen bond with R381 and the hydrophobic chain extending towards R378. The findings aid our understanding of the behavior and toxicity of PFASs on the thyroid hormone system.
[Mh] Termos MeSH primário: Ácidos Alcanossulfônicos/toxicidade
Caprilatos/toxicidade
Proteínas de Transporte/metabolismo
Fluorcarbonetos/toxicidade
Pré-Albumina/metabolismo
Globulina de Ligação a Tiroxina/metabolismo
[Mh] Termos MeSH secundário: Ácidos Alcanossulfônicos/sangue
Caprilatos/sangue
Proteínas de Transporte/genética
Fluorcarbonetos/sangue
Seres Humanos
Concentração Inibidora 50
Simulação de Acoplamento Molecular
Pré-Albumina/genética
Conformação Proteica
Relação Estrutura-Atividade
Hormônios Tireóideos/sangue
Hormônios Tireóideos/metabolismo
Tiroxina/metabolismo
Globulina de Ligação a Tiroxina/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkanesulfonic Acids); 0 (Caprylates); 0 (Carrier Proteins); 0 (Fluorocarbons); 0 (Prealbumin); 0 (Thyroid Hormones); 0 (Thyroxine-Binding Globulin); 947VD76D3L (perfluorooctanoic acid); 9H2MAI21CL (perfluorooctane sulfonic acid); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170512
[Lr] Data última revisão:
170512
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160817
[St] Status:MEDLINE


  5 / 57 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27483566
[Au] Autor:Lalic T; Beleslin B; Savic S; Stojkovic M; Ciric J; Zarkovic M
[Ti] Título:Challenges in interpretation of thyroid hormone test results.
[So] Source:Srp Arh Celok Lek;144(3-4):200-3, 2016 Mar-Apr.
[Is] ISSN:0370-8179
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: In interpreting thyroid hormones results it is preferable to think of interference and changes in concentration of their carrier proteins. OUTLINE OF CASES: We present two patients with discrepancy between the results of thyroid function tests and clinical status. The first case presents a 62-year-old patient with a nodular goiter and Hashimoto thyroiditis. Thyroid function test showed low thyroid-stimulating hormone (TSH) and normal to low fT4. By determining thyroid status (TSH, T4, fT4,T3, fT3) in two laboratories, basal and after dilution, as well as thyroxine-binding globulin (TBG), it was concluded that the thyroid hormone levels were normal. The results were influenced by heterophile antibodies leading to a false lower TSH level and suspected secondary hypothyroidism.The second case, a 40-year-old patient, was examined and followed because of the variable size thyroid nodule and initially borderline elevated TSH, after which thyroid status showed low level of total thyroid hormones and normal TSH. Based on additional analysis it was concluded that low T4 and T3 were a result of low TBG. It is a hereditary genetic disorder with no clinical significance. CONCLUSION: Erroneous diagnosis of thyroid disorders and potentially harmful treatment could be avoided by proving the interference or TBG deficiency whenever there is a discrepancy between the thyroid function results and the clinical picture.
[Mh] Termos MeSH primário: Anticorpos Heterófilos/sangue
Doenças Genéticas Ligadas ao Cromossomo X/sangue
Bócio Nodular/sangue
Doença de Hashimoto/sangue
Testes de Função Tireóidea/métodos
Hormônios Tireóideos/sangue
Tireotropina/sangue
Globulina de Ligação a Tiroxina/deficiência
Globulina de Ligação a Tiroxina/metabolismo
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Masculino
Meia-Idade
Tiroxina/sangue
Tri-Iodotironina/sangue
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Heterophile); 0 (Thyroid Hormones); 0 (Thyroxine-Binding Globulin); 06LU7C9H1V (Triiodothyronine); 9002-71-5 (Thyrotropin); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160803
[Lr] Data última revisão:
160803
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160804
[St] Status:MEDLINE


  6 / 57 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27411675
[Au] Autor:Henley D; Lightman S; Carrell R
[Ad] Endereço:Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, Australia; Faculty of Medicine, Dentistry and Health Sciences, School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia.
[Ti] Título:Cortisol and CBG - Getting cortisol to the right place at the right time.
[So] Source:Pharmacol Ther;166:128-35, 2016 Oct.
[Is] ISSN:1879-016X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Cortisol is transported in the blood by corticosteroid-binding globulin (CBG), a non-inhibitory member of the serpin family of serine protease inhibitors. Recent structural advances reveal how CBG acts as a releasing-agent as well as a carrier of cortisol. Taken together, the structures of the various forms of CBG and of the closely related thyroxine binding-globulin, show how the inherent conformational mechanism of the serpins has been adapted to modulate hormone release to the tissues by changes in binding affinities. A deduction from this, of the temperature dependence of hormone binding, is remarkably borne out with CBG, with a doubling in plasma free cortisol as the body temperature rises to 39°C. Another insight, against a dogma in the corticosteroid field, is that the proteolytic cleavage of CBG in inflammation results in a partial and not a complete loss of cortisol binding. This becomes of medical importance in conjunction with recent evidence of a pool of the circulating cleaved-form of CBG. It is now evident that tissue levels of free cortisol are buffered by two responsive plasma pools, intact CBG with a high binding-affinity and, particularly in inflammation and sepsis, a further pool of cleaved-CBG with a ten-fold lower affinity. The new molecular understandings, as well as providing insights into the differential release of circulating hormones, also open prospects for therapeutic interventions and draw attention to the potential of CBG and TBG as vehicles for the targeted delivery of drugs.
[Mh] Termos MeSH primário: Hidrocortisona/metabolismo
Transcortina/metabolismo
[Mh] Termos MeSH secundário: Temperatura Corporal
Sistemas de Liberação de Medicamentos/métodos
Liberação Controlada de Fármacos
Febre/fisiopatologia
Seres Humanos
Hidrocortisona/sangue
Inflamação/fisiopatologia
Ligação Proteica/fisiologia
Estrutura Quaternária de Proteína/fisiologia
Tiroxina/metabolismo
Globulina de Ligação a Tiroxina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Thyroxine-Binding Globulin); 9010-38-2 (Transcortin); Q51BO43MG4 (Thyroxine); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160715
[St] Status:MEDLINE


  7 / 57 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27350674
[Au] Autor:Ou H; Zhang Q; Zeng J
[Ad] Endereço:1Department of Biochemistry and Molecular Biology, Guizhou Medical University, Guiyang, Guizhou 550004, People's Republic of China.ouhailong@gmc.edu.cn.
[Ti] Título:Improving lipoprotein profiles by liver-directed gene transfer of low density lipoprotein receptor gene in hypercholesterolaemia mice.
[So] Source:J Genet;95(2):311-6, 2016 Jun.
[Is] ISSN:0973-7731
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:The defect of low density lipoprotein receptor disturbs cholesterol metabolism and causes familial hypercholesterolaemia (FH). In this study, we directly delivered exogenous Ldlr gene into the liver of FH model mice (Ldlr(-/-)) by lentiviral gene transfer system. The results showed that the Ldlr gene controlled by hepatocyte-specific human thyroxine-binding globulin (TBG) promoter successfully and exclusively expressed in livers.We found that, although, the content of high density lipoprotein in serum was not significantly affected by the Ldlr gene expression, the serum low density lipoprotein level was reduced by 46%, associated with a 30% and 28% decrease in triglyceride and total cholesterol, respectively, compared to uninjected Ldlr(-/-) mice. Moreover, the TBG directed expression of Ldlr significantly decreased the lipid accumulation in liver and reduced plaque burden in aorta (32%). Our results indicated that the hepatocyte-specific expression of Ldlr gene strikingly lowered serum lipid levels and resulted in amelioration of hypercholesterolaemia.
[Mh] Termos MeSH primário: Terapia Genética/métodos
Hiperlipoproteinemia Tipo II/terapia
Fígado/metabolismo
Placa Aterosclerótica/terapia
Receptores de LDL/genética
Transgenes
[Mh] Termos MeSH secundário: Animais
Aorta/metabolismo
Aorta/patologia
HDL-Colesterol/sangue
LDL-Colesterol/sangue
Modelos Animais de Doenças
Expressão Gênica
Vetores Genéticos/química
Vetores Genéticos/metabolismo
Hepatócitos/metabolismo
Hepatócitos/patologia
Seres Humanos
Hiperlipoproteinemia Tipo II/genética
Hiperlipoproteinemia Tipo II/metabolismo
Hiperlipoproteinemia Tipo II/patologia
Lentivirus/genética
Lentivirus/metabolismo
Fígado/patologia
Camundongos
Camundongos Transgênicos
Placa Aterosclerótica/genética
Placa Aterosclerótica/metabolismo
Placa Aterosclerótica/patologia
Regiões Promotoras Genéticas
Receptores de LDL/metabolismo
Globulina de Ligação a Tiroxina/genética
Globulina de Ligação a Tiroxina/metabolismo
Transfecção
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholesterol, HDL); 0 (Cholesterol, LDL); 0 (LDLR protein, human); 0 (Receptors, LDL); 0 (Thyroxine-Binding Globulin); 0 (Triglycerides)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160629
[St] Status:MEDLINE


  8 / 57 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27256229
[Au] Autor:Fang YL; Wang CL; Liang L
[Ad] Endereço:Department of Pediatrics, First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou 310003, China.
[Ti] Título:[Partial thyroxine binding globulin deficiency in test tube infants: report of cases and literature review].
[So] Source:Zhonghua Er Ke Za Zhi;54(6):428-32, 2016 Jun 02.
[Is] ISSN:0578-1310
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To investigate the clinical characteristics of twins with thyroxine binding globulin (TBG) deficiency and to find SERPINA7 gene mutations. METHOD: Data(2015) related to clinical characteristics, serum biochemistry, gene mutations and pedigree of two children with TBG deficiency were collected in the First Affiliated Hospital of College of Medicine, Zhejiang University. The related literature was searched form China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, National Center for Biotechnology Information and PubMed (up to December 2015) by using search terms "Thyroxine binding globulin deficiency, gene, mutation" . RESULT: Both patients were diagnosed as central hypothyroidism at the beginning and treated with L-thyroxine. Both of the identical twins of the triplet were observed for mutation in exon3, c. 631Gï¹¥A(p.A211T), a new mutation had not been reported, but their parents and another non-identical triplet brother were normal. Literature review showed that 23 foreign cases with SERPINA7 gene mutation had been reported, however, no Chinese with SERPINA7 gene mutation had been reported. Among reported cases it was shown that SERPINA7 gene mutations located in exon, intron, promoter and enhancer. Up to now, 49 variants had been identified, 41 of them located in the mutated genes. Including these two cases, patients with thyroxine binding globulin deficiency were characterized by reduced serum TH levels, but normal free TH and TSH and absence of clinical manifestations. CONCLUSION: The new mutation of SERPINA7 gene c. 631Gï¹¥A(p.A211T)is not transmitted via the known X chromosome linked heredity, and as the cases were test tube triplet infants, it is a de novo mutation. The serum thyroid function tests of TBG deficiency showed decreased TT4, TT3 and normal TSH and TBG deficiency is often misdiagnosed as central hypothyroidism.
[Mh] Termos MeSH primário: Doenças Genéticas Ligadas ao Cromossomo X/diagnóstico
Globulina de Ligação a Tiroxina/deficiência
[Mh] Termos MeSH secundário: Criança
China
Éxons
Seres Humanos
Lactente
Íntrons
Masculino
Mutação
Linhagem
Regiões Promotoras Genéticas
Testes de Função Tireóidea
Tiroxina/uso terapêutico
Globulina de Ligação a Tiroxina/genética
Trigêmeos
Gêmeos Monozigóticos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (SERPINA7 protein, human); 0 (Thyroxine-Binding Globulin); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170130
[Lr] Data última revisão:
170130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160604
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1310.2016.06.008


  9 / 57 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26885894
[Au] Autor:Hui-Yuen JS; Christiano AM; Askanase A
[Ad] Endereço:a Division of Pediatric Rheumatology, Cohen Children's Medical Center , North Shore-Long Island Jewish Hospital , New York , USA.
[Ti] Título:Sex differences in genomics in lupus: girls with systemic lupus have high interferon gene expression while boys have high levels of tumour necrosis factor-related gene expression.
[So] Source:Scand J Rheumatol;45(5):394-6, 2016 Oct.
[Is] ISSN:1502-7732
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Systemic lupus erythematosus (SLE) is a chronic disease occurring up to 15 times more frequently in females than males. This bias extends to possible differences in disease flares and response to therapy. This study was initiated to investigate the differences between girls and boys with childhood-onset SLE (cSLE) at the molecular level. METHOD: We analysed the Gene Expression Omnibus National Center for Biotechnology Information (GEO NCBI) microarray data available for 88 girls and 16 boys with treatment-naïve cSLE and compared the results to those from healthy controls. Transcriptional profiles were generated using the platforms of Affymetrix U133A and U133B gene chips and Bioconductor/R programming packages were used to process and compare the data. RESULTS: Girls with cSLE overexpressed an interferon (IFN)-α signature that was absent in boys. Boys with cSLE were observed to overexpress tumour necrosis factor-related genes that were absent in girls. Both boys and girls were observed to overexpress several genes related to granulopoeisis. CONCLUSIONS: Our results suggest a potential application of genomics to differentially predict response to therapy between females and males with SLE.
[Mh] Termos MeSH primário: Interferons/genética
Lúpus Eritematoso Sistêmico/genética
Fatores Sexuais
Transcriptoma
[Mh] Termos MeSH secundário: Adolescente
Antígenos/genética
Proteínas de Transporte/genética
Estudos de Casos e Controles
Criança
Proteínas do Citoesqueleto/genética
Feminino
Receptor Quinase 1 Acoplada a Proteína G/genética
Expressão Gênica
Genômica
Seres Humanos
Peptídeos e Proteínas de Sinalização Intracelular/genética
Modelos Lineares
Masculino
Proteínas de Membrana/genética
Análise em Microsséries
Proteínas Mitocondriais/genética
Proteínas do Tecido Nervoso/genética
Proteínas Nucleares/genética
Proteínas Tirosina Fosfatases Classe 2 Semelhantes a Receptores/genética
Lectina 1 Semelhante a Ig de Ligação ao Ácido Siálico/genética
Globulina de Ligação a Tiroxina/genética
Fatores de Transcrição/genética
Proteínas Supressoras de Tumor/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens); 0 (Carrier Proteins); 0 (Cytoskeletal Proteins); 0 (DCF1 protein, human); 0 (IFI44 protein, human); 0 (IFI6 protein, human); 0 (IFIT1 protein, human); 0 (IFIT3 protein, human); 0 (Intracellular Signaling Peptides and Proteins); 0 (Membrane Proteins); 0 (Mitochondrial Proteins); 0 (Narf protein, human); 0 (Nerve Tissue Proteins); 0 (Nuclear Proteins); 0 (SERPINA7 protein, human); 0 (SIGLEC1 protein, human); 0 (Sialic Acid Binding Ig-like Lectin 1); 0 (TP63 protein, human); 0 (Thyroxine-Binding Globulin); 0 (Transcription Factors); 0 (Tumor Suppressor Proteins); 9008-11-1 (Interferons); EC 2.7.11.14 (G-Protein-Coupled Receptor Kinase 1); EC 2.7.11.14 (GRK1 protein, human); EC 3.1.3.48 (PTPRD protein, human); EC 3.1.3.48 (Receptor-Like Protein Tyrosine Phosphatases, Class 2)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170422
[Lr] Data última revisão:
170422
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160218
[St] Status:MEDLINE
[do] DOI:10.3109/03009742.2015.1132760


  10 / 57 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26731573
[Au] Autor:Pedersen C; Leserman J; Garcia N; Stansbury M; Meltzer-Brody S; Johnson J
[Ad] Endereço:Department of Psychiatry, The University of North Carolina at Chapel Hill, CB# 7160, Chapel Hill, NC 27599, United States. Electronic address: cort_pedersen@med.unc.edu.
[Ti] Título:Late pregnancy thyroid-binding globulin predicts perinatal depression.
[So] Source:Psychoneuroendocrinology;65:84-93, 2016 Mar.
[Is] ISSN:1873-3360
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Previously we found that late pregnancy total and free thyroxine (TT4, FT4) concentrations were negatively related to greater pre and/or postpartum depressive symptoms. In a much larger cohort, the current study examined whether these thyroid indices measured earlier in the third trimester (31-33 weeks) predict subsequent perinatal depression and anxiety ratings as well as syndromal depression. Thyroid-binding globulin (TBG) concentrations increase markedly during pregnancy and may be an index of sensitivity to elevated estrogen levels. TBG was examined in this study because prior findings suggest that postpartum depression is related to sensitivity to mood destabilization by elevated sex hormone concentrations during pregnancy. Our cohort was 199 euthyroid women recruited from a public health obstetrics clinic (63.8% Hispanic, 21.6% Black). After screening and blood draws for hormone measures at pregnancy weeks 31-33, subjects were evaluated during home visits at pregnancy weeks 35-36 as well as postpartum weeks 6 and 12. Evaluations included psychiatric interviews for current and life-time DSM-IV psychiatric history (M.I.N.I.-Plus), subject self-ratings and interviewer ratings for depression and anxiety (Edinburgh Postnatal Depression Scale, Montgomery-Ǻsberg Depression Rating Scale; Spielberger State-Trait Anxiety Inventory, Hamilton Anxiety Inventory), as well as a standardized interview to obtain life-time trauma history. Numerous covariates were included in all regression analyses. Trauma and major depression history were robustly significant predictors of depression and anxiety ratings over the study period when these variables were analyzed individually or in a combined model including FT4 or TBG (p<.001). When analyzed alone, FT4 levels were a less strong but still significant predictor of all depression and anxiety ratings (p<.05) while TBG levels was a significant or nearly significant predictor of most ratings. FT4, TBG and trauma history, but not major depression history, were significant individual predictors of syndromal depression during the study period (p<.05) in single predictor models. In models combining each with trauma and major depression history, FT4 and TBG generally were not significantly predictive of depression or anxiety ratings, and FT4 was also not a significant predictor of syndromal depression: however, in the combined model TBG was a particularly strong predictor of perinatal syndromal depression (p=.005) and trauma history was also significant (p=.016). Further study of the interactions among TBG, FT4, sex hormones, trauma history and perinatal depression may provide insights into the pathophysiological basis of individual variance in vulnerability to mood destabilization by the hormone conditions of pregnancy.
[Mh] Termos MeSH primário: Depressão Pós-Parto/sangue
Globulina de Ligação a Tiroxina/metabolismo
[Mh] Termos MeSH secundário: Adulto
Ansiedade/sangue
Ansiedade/etiologia
Ansiedade/psicologia
Depressão Pós-Parto/etiologia
Depressão Pós-Parto/psicologia
Transtorno Depressivo Maior/sangue
Transtorno Depressivo Maior/diagnóstico
Feminino
Seres Humanos
Valor Preditivo dos Testes
Gravidez
Complicações na Gravidez/sangue
Complicações na Gravidez/etiologia
Complicações na Gravidez/psicologia
Terceiro Trimestre da Gravidez
Escalas de Graduação Psiquiátrica
Tireoglobulina/sangue
Glândula Tireoide/fisiologia
Tireotropina/sangue
Tiroxina/sangue
Tri-Iodotironina/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Thyroxine-Binding Globulin); 06LU7C9H1V (Triiodothyronine); 9002-71-5 (Thyrotropin); 9010-34-8 (Thyroglobulin); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170301
[Lr] Data última revisão:
170301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160106
[St] Status:MEDLINE



página 1 de 6 ir para página                
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde